GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Scandion Oncology A/S (OSTO:SCOL) » Definitions » Short Percentage of Float

Scandion Oncology A/S (OSTO:SCOL) Short Percentage of Float


View and export this data going back to 2018. Start your Free Trial

What is Scandion Oncology A/S Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Scandion Oncology A/S's Short Percentage of Float

For the Biotechnology subindustry, Scandion Oncology A/S's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Scandion Oncology A/S's Short Percentage of Float Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Scandion Oncology A/S's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Scandion Oncology A/S's Short Percentage of Float falls into.


Scandion Oncology A/S (OSTO:SCOL) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Scandion Oncology A/S (OSTO:SCOL) » Definitions » Short Percentage of Float
Comparable Companies
OSTO:EXPRS2 OSTO:COMBI XSAT:ABERA OSTO:LPGO NGM:COEGIN XSAT:CHOSA OSTO:2CUREX OSTO:BIOSGN XSAT:APTA XSAT:DBP B OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
8VY:Germany
Address
Fruebjergvej 3, Symbion, Copenhagen, DNK, 2100
Website
https://www.scandiononcology.com
Scandion Oncology A/S is a clinical-stage biotechnology company developing first-in-class medicines aimed at treating cancer that is resistant to current treatment options. Cancer Drug Resistance Company discovers and develops first-in-class medicines aimed at treating cancer that is resistant to current treatment options.

Scandion Oncology A/S (OSTO:SCOL) Headlines

No Headlines